Rotarix Launch Planned For Second Half; GSK Touts Quick Dosing Schedule
Executive Summary
GlaxoSmithKline will launch its rotavirus gastroenteritis vaccine Rotarix in the U.S. in the second half of the year after FDA granted approval April 3. The two-course vaccine will offer a dosing advantage over Merck's existing rotavirus vaccine RotaTeq, which is administered over three courses
You may also be interested in...
GSK Tackles Rotarix Risks Head On, Clearing Way For Panel’s Support
With a positive advisory committee recommendation, GlaxoSmithKline's rotavirus vaccine Rotarix is proving to be a successful example of handling a known risk factor by working closely with FDA, prospectively assessing the risk potential and developing a comprehensive pharmacovigilance plan
Wyeth Withdraws RotaShield Ahead Of Rotavirus Season And ACIP Review
Wyeth-Lederle Vaccines is withdrawing the RotaShield rotavirus vaccine because recently gathered epidemiological data continue to suggest links to intussusception.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.